IDEX said net sales for fiscal 2024 were $3,268.8 million, flat overall and down 2% organically, and diluted EPS were $6.64, down 15%.

1. 01

   IDEX said net sales for fiscal 2024 were $3,268.8 million, flat overall and down 2% organically, and diluted EPS were $6.64, down 15%.

2. 02

   The company completed the acquisition of Mott on September 5, 2024 for cash consideration of $986.2 million, net of cash acquired, using $211.9 million of cash on hand and $774.3 million of debt.

3. 03

   IDEX said operating cash flow for fiscal 2024 was $668.1 million, down 7%, and represented 132% of net income, while free cash flow was $603.0 million, down 4%, and represented 101% of adjusted net income.

4. 04

   IDEX said net sales were relatively flat compared with the prior year, with acquisitions, net of divestitures, increasing net sales by 2% and organic net sales decreasing by 2%. The company cited lower volumes resulting from market conditions, primarily in the Health & Science Technologies segment, as the driver of the organic net sales decrease.

Key figures

Fiscal year ended December 31, 2024

Revenue

$3.3B

Operating income

$677M

Net income

$505M

EPS

$6.64

Gross profit

$1.4B

Operating cash flow

$668M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.